B-cell therapies in established rheumatoid arthritis

Best Practice and Research: Clinical Rheumatology

Volumn 25, Issue 4, 2011, Pages 535-548

  Leandro, Maria J ^a   Becerra Fernandez, Elena ^a,b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

Author keywords

B cell depletion; B cell therapies; B cells; Rheumatoid arthritis; Rituximab

Indexed keywords

ABATACEPT; ADALIMUMAB; CYCLOPHOSPHAMIDE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; LEFLUNOMIDE; METHOTREXATE; PLACEBO; RHEUMATOID FACTOR; RITUXIMAB; TENOFOVIR;

B CELL DEPLETION THERAPY; B LYMPHOCYTE; CELL THERAPY; CHRONIC HEPATITIS; CLINICAL PRACTICE; CRYPTOCOCCAL MENINGITIS; CYTOMEGALOVIRUS INFECTION; DISEASE ACTIVITY; DISEASE REGISTRY; DISEASE SEVERITY; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG USE; FOLLOW UP; HEPATITIS B; HOSPITAL INFECTION; HUMAN; IMMUNOGLOBULIN DEFICIENCY; INFECTION; INFECTION RISK; LOW DRUG DOSE; MONOTHERAPY; NONHUMAN; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; RETREATMENT; REVIEW; RHEUMATOID ARTHRITIS; TREATMENT OUTCOME; TREATMENT RESPONSE;

AGAMMAGLOBULINEMIA; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; B-LYMPHOCYTES; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INFECTION; MALE; METHOTREXATE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT FAILURE;

EID: 82955178197     PISSN: 15216942     EISSN: 15321770     Source Type: Journal    
DOI: 10.1016/j.berh.2011.10.005     Document Type: Review

References (76)

1. J.C. Edwards, and G. Cambridge Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes Rheumatology (Oxford) 40 2001 205 211
2. J.C. Edwards, L. Szczepanski, and J. Szechinski Efficacy of B-cell targeted therapy with rituximab in patients with rheumatoid arthritis New England Journal of Medicine 350 2004 24 33
3. P. Emery, R. Fleischmann, and A. Filipowicz-Sosnowska The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results from a phase IIb randomized, double-blind, placebo-controlled, dose-ranging trial Arthritis and Rheumatism 54 2006 1390 1400
4. S.B. Cohen, P. Emery, and M.W. Greenwald Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks Arthritis and Rheumatism 54 2006 2793 2806 (Pubitemid 44497758)
5. C. Popa, M.J. Leandro, G. Cambridge, and J.C.W. Edwards Repeated B lymphocyte depletion with rituximab in rheumatoid arthritis over 7 yrs Rheumatology (Oxford) 46 2007 626 630 (Pubitemid 46523308)
6. E. Keystone, R. Fleischmann, and P. Emery Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: an open-label extension analysis Arthritis and Rheumatism 56 2007 3896 3908 (Pubitemid 350262316)
7. E. Keystone, R. Fleischmann, and P. Emery Multiple courses of rituximab produce sustained efficacy in patients with rheumatoid arthritis with an inadequate response to one or more TNF inhibitors Arthritis and Rheumatism 62 Suppl. 10 2010 321
8. M.E. Reff, K. Carner, and K.S. Chambers Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20 Blood 83 1994 435 445 (Pubitemid 24030569)
9. K.C. Anderson, M.P. Bates, and B.L. Slaughenhoupt Expression of human B cell-associated antigens on leukemias and lymphomas: a model of human B cell differentiation Blood 63 1984 1424 1433 (Pubitemid 14120390)
10. D.G. Maloney, A.J. Grillo-Lopez, and C.A. White IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma Blood 90 1997 2188 2195 (Pubitemid 27392702)
11. M.J. Leandro, N. Cooper, and G. Cambridge Bone marrow B-lineage cells in patients with rheumatoid arthritis following rituximab therapy Rheumatology (Oxford) 46 2007 29 36 (Pubitemid 44932780)
12. M.J. Leandro, G. Cambridge, M.R. Ehrenstein, and J.C. Edwards Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis Arthritis and Rheumatism 54 2006 613 620 (Pubitemid 43228639)
13. P. Roll, A. Palanichamy, and C. Kneitz Regeneration of B cell subsets after transient B cell depletion using anti-CD20 antibodies in rheumatoid arthritis Arthritis and Rheumatism 54 2006 2377 2386 (Pubitemid 44204997)
14. E. Keystone, P. Emery, and C.G. Peterfy Rituximab inhibits structural joint damage in patients with rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitor Annals of the Rheumatic Diseases 68 2009 216 221
15. S.B. Cohen, E. Keystone, and M.C. Genovese Continued inhibition of structural damage over 2 years in patients with rheumatoid arthritis treated with rituximab in combination with methotrexate Annals of the Rheumatic Diseases 69 2010 1158 1161
16. A. Finckh, A. Ciurea, and L. Brulhart B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents Arthritis and Rheumatism 56 2007 1417 1423 (Pubitemid 46764068)
17. A. Finckh, A. Ciurea, and L. Brulhart Which subgroup of patients with rheumatoid arthritis benefits from switching to rituximab versus alternative anti-tumour necrosis factor agents Annals of the Rheumatic Diseases 69 2010 387 393
18. B.V. Cruyssen, P. Durez, and R. Westhovens The Belgian MIRA (MAbThera In Rheumatoid Arthritis) registry: clues for optimization of rituximab treatment strategies Arthritis Research & Therapy 12 2010 R169
19. M.H. Buch, J.S. Smolen, and N. Betteridge Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis Annals of the Rheumatic Diseases 70 2011 909 920
20. J. Gottenberg, X. Puechal, and M. Debandt Treatment of rheumatoid vasculitis with rituximab: data from the French registry AIR (Autoimmunity and Rituximab) Annals of the Rheumatic Diseases 67 Suppl. II 2008 227
21. P.A. Chandra, Y. Margulis, and C. Schiff Rituximab is useful in the treatment of Felty's syndrome American Journal of Therapeutics 15 2008 321 322
22. G. Assmann, M. Pfreundschuh, and J. Voswinkel Rituximab in patients with rheumatoid arthritis and vasculitis-associated cutaneous ulcers Clinical and Experimental Rheumatology 28 Suppl. 57 2010 81 83
23. B. Iaccheri, S. Androudi, and E.B. Bocci Rituximab treatment for persistent scleritis associated with rheumatoid arthritis Ocular Immunology and Inflammation 18 2010 223 225
24. S. Chauhan, A. Kamal, and R.N. Thompson Rituximab for treatment of scleritis associated with rheumatoid arthritis British Journal of Ophthalmology 93 2009 984 985
25. M. Albert, E. Beltrán, and L. Martínez-Costa Rituximab in rheumatoid arthritis-associated peripheral ulcerative keratitis Archivos de la Sociedad Española de Oftalmología 86 2011 118 120
26. J. Narvaez, M.V. Hernandez, and J.M. Ruiz Rituximab therapy for AA-amyloidosis secondary to rheumatoid arthritis Joint Bone Spine 78 2001 101 103
27. D. McGonagle, A.L. Tan, and J. Madden Rituximab use in everyday clinical practice as a first-line biologic therapy for the treatment of DMARD-resistant rheumatoid arthritis Rheumatology (Oxford) 47 2008 865 867 (Pubitemid 351796374)
28. A. Rubbert-Roth, P.P. Tak, and C. Zerbini Efficacy and safety of various repeat treatment dosing regimens of rituximab in patients with active rheumatoid arthritis: results of a phase II randomized study (MIRROR) Rheumatology (Oxford) 49 2010 1683 1693
29. P. Emery, A. Deodhar, and W.F. Rigby Efficacy and safety of different doses and retreatment of rituximab: a randomized, placebo-controlled trial in patients who are biological naïve with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab's Efficacy in MTX inadequate responders (SERENE)) Annals of the Rheumatic Diseases 69 2010 1629 1635
30. Chatzidionysiou K, Lie E, Nasonov E, et al. Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries. Annals of the Rheumatic Diseases, in press.
31. Solau-Gervais E, Prudhomme C, Philippe P, et al. Efficacy of rituximab in the treatment of rheumatoid arthritis. Influence of serologic status, coprescription of methotrexate and prior TNF-alpha inhibitors exposure. Joint Bone Spine, in press.
32. J.E. Loveless, E. Olech, and C. Pritchard An open-label, prospective study of the safety of rituximab in combination with disease-modifying anti-rheumatic drugs in patients with active rheumatoid arthritis (SUNDIAL) Arthritis and Rheumatism 60 2009 S1660
33. E.M. Vital, S. Dass, and A.C. Rawstron Combination rituximab and leflunomide produces lasting responses in rheumatoid arthritis Annals of the Rheumatic Diseases 67 Suppl. II 2008 901
34. J.C. Henes, J. Schedel, L. Kanz, and I. Koetter Rituximab and concomitant leflunomide for the treatment of rheumatoid arthritis Rheumatology International 30 2010 709 712
35. C. Gabay, K. Chatsicionysou, and E. Lie Effectiveness of different DMARD cotherapies in rituximab-treated rheumatoid arthritis patients. Results of a one-year follow up study from the CERRERA collaboration Arthritis and Rheumatism 62 Suppl. 10 2010 1802 [abstract]
36. MabThera (Rituximab) Summary of product characteristics October 2010 http://www.medicines.org.uk/EMC/medicine/2570/SPC/ Mabthera+100mg+and+500mg+concentrate+for+solution+for+infusion/
37. R.F. van Vollenhoven, P. Emery, and C.O. Bingham II Long-term safety of patients receiving rituximab in rheumatoid arthritis clinical trials Journal of Rheumatology 37 2010 558 567
38. F. Breedveld, S. Agarwal, and M. Yin Rituximab pharmacokinetics in patients with rheumatoid arthritis: B-cell levels do not correlate with clinical response Journal of Clinical Pharmacology 47 2007 1119 1128
39. N. Blank, R. Max, and M. Schiller Safety of combination therapy with rituximab and etanercept for patients with rheumatoid arthritis Rheumatology (Oxford) 48 2009 440 441
40. M.W. Greenwald, W.J. Shergy, and J.L. Kaine Evaluation of the safety of rituximab in combination with a tumor necrosis factor inhibitor and methotrexate in patients with rheumatoid arthritis: results from a randomized controlled trial Arthritis and Rheumatism 63 2011 622 632
41. M.C. Genovese, F. Breedveld, and P. Emery Rate of serious infections in RA patients who subsequently receive other biologic therapies after discontinuing rituximab treatment Arthritis and Rheumatism 62 2010 S403
42. J. Gottenberg, R. Flipo, and A. Cantagrel Switching from rituximab to abatacept: tolerance data of 179 patients prospectively followed up in the "Orencia in Rheumatoid Arthritis" (ORA) registry Annals of the Rheumatic Diseases 69 Suppl. 3 2010 385
43. P.P. Tak, W.F. Rigby, and A. Rubbert-Roth Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial Annals of the Rheumatic Diseases 70 2011 39 46
44. E.M. Vital, A.C. Rawstron, and S. Dass Reduced-dose rituximab in rheumatoid arthritis: efficacy depends on degree of B cell depletion Arthritis and Rheumatism 63 2011 603 608
45. M.J. Leandro, J.C. Edwards, and G. Cambridge Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion Annals of the Rheumatic Diseases 61 2001 883 888
46. E.M. Vital, S. Dass, and M.H. Buch A randomized double-blind placebo controlled trial on the effects of increased dose rituximab in patients with initial incomplete depletion - the extended treatment with rituximab in rheumatoid arthritis (EXTRRA) trial Annals of the Rheumatic Diseases 69 Suppl. 3 2010 147
47. P.J. Mease, S. Cohen, and N.B. Gaylis Efficacy and safety of retreatment in patients with rheumatoid arthritis with previous inadequate response to tumor necrosis factor inhibitors: results from the SUNRISE trial Journal of Rheumatology 37 2010 917 927
48. M. Bukhari, R. Abernethy, and C. Deighton BSR and BHPR guidelines on the use of rituximab in rheumatoid arthritis Rheumatology (Oxford) 2011 May 4 [Epub ahead of print]
49. P. Emery, P. Mease, and A. Rubbert Retreatment with rituximab (RTX) based on a treatment to target (TT) approach provides better disease control than treatment as needed (PRN) in patients with rheumatoid arthritis Arthritis and Rheumatism 60 2009 S2013
50. R.M. Thurlings, K. Vos, D.M. Gerlag, and P.P. Tak Disease activity-guided rituximab therapy in rheumatoid arthritis: the effects of re-treatment in initial nonresponders versus initial responders Arthritis and Rheumatism 58 2008 3657 3664
51. R.F. Van Vollenhoven, K. Chatzidionysiou, and C. Gabay Rheumatoid factor predicts response to rituximab in a European registry-based cohort: 6-month results from the collaborative European registries for rituximab in rheumatoid arthritis (CERERRA) Annals of the Rheumatic Diseases 68 Suppl. 3 2009 579
52. S. Dass, A. Rawstron, and E. Vital Highly sensitive B cell analysis predicts response to rituximab therapy in rheumatoid arthritis Arthritis and Rheumatism 58 2008 2993 2999
53. A. Strangfeld, M. Eveslage, and J. Kekow Effectiveness of treatment with rituximab depends on autoantibody status - results from 2 years experience in the German biologics register RABBIT Arthritis and Rheumatism 60 2009 S1695
54. J.D. Isaacs, E. Olech, and P.P. Tak Autoantibody-positive rheumatoid arthritis patients have enhanced clinical response to rituximab when compared with seronegative patients Annals of the Rheumatic Diseases 68 Suppl. 3 2009 442
55. G.J. Silverman, S. Schwartzman, and M. Townsend Identification of biomarkers for enhanced benefit to rituximab in rheumatoid arthritis: role of autoantibodies and inflammatory markers Arthritis and Rheumatism 60 2009 S1680
56. L. Quartuccio, M. Fabris, and S. Salvin Rheumatoid factor positivity rather than anti-CCP positivity, a lower disability and a lower number of anti-TNF agents failed are associated with response to rituximab in rheumatoid arthritis Rheumatology (Oxford) 48 2009 1557 1559
57. J. Wendler, S. Wassenberg, and H.P. Tony Predictive value of rheumatoid factor titre for treatment response to rituximab in the "German rituximab treatment of active rheumatoid arthritis in daily practice" trial Annals of the Rheumatic Diseases 69 Suppl. 3 2010 546
58. J. Sellam, H. Hendel-Chavez, and S. Rouanet B cell activation biomarkers as predictive factors for the response to rituximab in rheumatoid arthritis: a six-month, national, multicentre, open-label study Arthritis and Rheumatism 63 2011 933 938
59. H.E. Mei, D. Frolich, and C. Giesecke Steady-state generation of mucosal IgA+ plasmablasts is not abrogated by B-cell depletion therapy with rituximab Blood 116 2010 5181 5190
60. E.E.A. Arts, T.L. Jansen, and A. Den Broeder Statins inhibit the antirheumatic effects of rituximab in rheumatoid arthritis: results from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry Annals of the Rheumatic Diseases 70 2011 877 878
61. H. Bastian, S. Zinke, and K. Egerer Effects of early rituximab retreatment in rheumatoid arthritis patients with an inadequate response after the first cycle: retrospective arthritis cohort study Journal of Rheumatology 37 2010 1069 1071
62. R. Van Vollenhoven, P. Emery, and C.O. Bingham Long-term safety of rituximab: follow-up of the rheumatoid arthritis clinical trials and retreatment population Arthritis and Rheumatism 2010 abstract 391
63. X. Mariette, J.E. Gottenberg, P. Ravaud, and B. Combe Registries in rheumatoid arthritis and autoimmune diseases: data from the French registries Rheumatology (Oxford) 50 2011 222 229
64. J.R. Curtis, F. Xie, and L. Chen The comparative risk of serious infections among rheumatoid arthritis patients starting or switching biological agents Annals of the Rheumatic Diseases 70 2011 1401 1406
65. D.E. Furst Serum immunoglobulins and risk of infection: how low can you go? Seminars in Arthritis and Rheumatism 2008
66. R.M. Fleischmann Progressive multifocal leukoencephalopathy following rituximab treatment in a patient with rheumatoid arthritis Arthritis and Rheumatism 60 2009 3225 3228
67. Clifford DB, Ances B, Costello C, et al. Rituximab-associated progressive multifocal leukoencephalopahty in rheumatoid arthritis. Archives of Neurology, in press.
68. E.S. Molloy, and L.H. Calabrese Progressive multifocal leukoencephalopathy: a national estimate of frequency in systemic lupus erythematosus and other rheumatic diseases Arthritis and Rheumatism 60 2009 3761 3765
69. A. Pyrpasopoulou, S. Douma, and T. Vassiliadis Reactivation of chronic hepatitis B virus infection following rituximab administration for rheumatoid arthritis Rheumatology International 31 2011 403 409
70. W. Yeo, T.C. Chan, and W.Y. Leung Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab Journal of Clinical Oncology 27 2009 605 611
71. Koo YX, Tay M, Teh YE, et al. Risk of hepatitis B virus (HBV) reactivation in hepatitis B surface antigen negative/hepatitis B core antibody positive patients receiving rituximab-containing combination chemotherapy without routine antiviral prophylaxis. Annals of Hematology, in press.
72. Ohishi W, Chayama K. Prevention of hepatitis B virus reactivation in immunosuppressive therapy or chemotherapy. Clinical and Experimental Nephrology, in press.
73. Wingfield T, Jani M, Krutikov, et al. Cryptococcal meningitis in an HIV-negative patient with rheumatoid arthritis treated with rituximab. Rheumatology, in press.
74. H. Vallet, R. Houitte, A. Azria, and X. Mariette Cytomegalovirus colitis and hypo-IgG after rituxima therapy for rheumatoid arthritis Journal of Rheumatology 38 2011 965 966
75. L.L. Teichmann, M. Woenckhaus, and C. Vogel Fatal Pneumocystis pneumonia following rituximab administration for rheumatoid arthritis Rheumatology 47 2008 1256 1257 (Pubitemid 352038242)
76. G. Wheater, V.E. Hogan, and Y.K. Teng Supression of bone turnover by B-cell depletion in patients with rheumatoid arthritis Ostoporos Int. 2011 Apr 6 [Epub ahead of print]